About Lumateperone Tosylate API
Therapeutic CategoryCentral Nervous System (CNS)

CAS Number
313368-91-1
API Technology
Synthetic
Dose Form
Oral Solid/Capsules
Dr Reddy's Development Status
Available
Available Regulatory Filing
USDMF, Brazil DMF
Mechanism of Action
The mechanism of action of lumateperone in the treatment of schizophrenia is unknown. However, the efficacy of lumateperone could be mediated through a combination of antagonist activity at central serotonin 5-HT2A receptors and postsynaptic antagonist activity at central dopamine D2 receptors.
Indication
CAPLYTA is an atypical antipsychotic indicated for the treatment of schizophrenia in adults.
Related APIs
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!
Related Resources
FAQs
Treats schizophrenia and bipolar depression
Available as oral capsules: 42 mg
Modulates serotonergic, dopaminergic, and glutamatergic neurotransmission Reduces symptoms of schizophrenia and bipolar depression with minimal side effects
Store at 2°C to 8°C (36°F to 46°F), in a cool, dry place
Disclaimer
No information on this website, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patent Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including, patent scenario in their respective markets and will be responsible for all patent related liabilities Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.